BioAge Labs Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOA research report →
Range $21 – $40
Price Chart
About the company
BioAge Labs, Inc. , a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
- CEO
- Kristen Fortney
- IPO
- 2024
- Employees
- 61
- HQ
- Emeryville, CA, US
Get TickerSpark's AI analysis on BIOA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $236.82M
- P/E
- -2.64
- PEG
- 0.36
- P/S
- 22.87
- P/B
- 0.75
- EV/EBITDA
- -1.76
- Div Yield
- 0.00%
- Gross Margin
- 99.39%
- Op Margin
- -1026.28%
- Net Margin
- -912.25%
- ROE
- -28.99%
- ROIC
- -28.08%
Latest fiscal year · YoY change
- Revenue
- $8.99M+0.0%
- Gross Profit
- $8.99M+0.0%
- Op Income
- $-92,780,000
- Net Income
- $-80,605,000-13.4%
- EPS
- $-2.24-13.1%
- OCF Growth
- -58.4%
- FCF Growth
- -58.7%
- 52W High
- $25.96
- 52W Low
- $5.04
- 50D MA
- $10.25
- 200D MA
- $16.67
- Beta
- 0.94
- RSI (14)
- 23
- Avg Volume
- 874.34K
No earnings-call transcripts are available for BIOA yet.
- Free Float
- 84.1%
- Shares Outstanding
- 37.65M
- Float Shares
- 31.67M
of shares held by institutions
148 13F filers
Buy/sell ratio 1.21. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ah Capital Management, L.L.C. | 3.23M | 0 |
| Blackrock, Inc. | 2.85M | ▲ 581.32K |
| Cormorant Asset Management, LP | 2.39M | ▼ 500.00K |
| Sofinnova Investments, Inc. | 2.29M | 0 |
| Jupiter Topco LLC | 2.14M | ▲ 2.14M |
| Janus Henderson Group Ltd. | 2.09M | ▲ 1.69M |
| Octagon Capital Advisors LP | 1.75M | 0 |
| Ra Capital Management, L.P. | 1.67M | ▲ 21.00K |
| Bioimpact Capital LLC | 1.67M | ▲ 1.67M |
| Vanguard Capital Management LLC | 1.54M | ▲ 189.31K |
| Vanguard Group Inc | 1.41M | ▼ 236.48K |
| Polar Capital Holdings PLC | 1.07M | ▼ 60.30K |
Held by 181 ETFs
Biggest fund positions in BIOA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 26 | Barton Shane | other | 14,198 |
| Jun 30, 26 | Barton Shane | other | 7,861 |
| Jun 29, 26 | Barton Shane | other | 14,198 |
| Jun 29, 26 | Barton Shane | other | 8,958 |
| Jun 29, 26 | Barton Shane | other | 8,958 |
| Jun 30, 26 | Barton Shane | other | 4,065 |
| Jun 29, 26 | Barton Shane | other | 7,261 |
| Jun 30, 26 | Barton Shane | other | 7,861 |
| Jun 29, 26 | Barton Shane | other | 7,261 |
| Jun 29, 26 | Barton Shane | other | 9,301 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BIOA coverage
Recent articles, reports, and earnings notes.
No research on BIOA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIOA report →Bank of America Corp DE Buys 257,855 Shares of BioAge Labs, Inc. $BIOA
defenseworld.net · Sep 28
BioAge Labs to Present at Upcoming Investor Conferences
globenewswire.com · Sep 25
BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 16
BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
seekingalpha.com · Sep 9
BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema
globenewswire.com · Sep 8
BioAge: CV Risk Data Due H2 A Major Catalyst After Rival's Data Causes Sell-Off
seekingalpha.com · Sep 5
BioAge Labs to Present at Upcoming Investor Conferences
globenewswire.com · Sep 2
214,546 Shares in BioAge Labs, Inc. $BIOA Purchased by Dimensional Fund Advisors LP
defenseworld.net · Aug 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.